WO1992009311A1 - Biocompatible synthetic double-wall vascular prosthesis containing hormone-secreting cells - Google Patents
Biocompatible synthetic double-wall vascular prosthesis containing hormone-secreting cells Download PDFInfo
- Publication number
- WO1992009311A1 WO1992009311A1 PCT/EP1991/002258 EP9102258W WO9209311A1 WO 1992009311 A1 WO1992009311 A1 WO 1992009311A1 EP 9102258 W EP9102258 W EP 9102258W WO 9209311 A1 WO9209311 A1 WO 9209311A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tubular element
- tubular
- web
- prosthesis according
- comprised
- Prior art date
Links
- 229940088597 hormone Drugs 0.000 title claims abstract description 13
- 239000005556 hormone Substances 0.000 title claims abstract description 13
- 230000003248 secreting effect Effects 0.000 title claims abstract description 8
- 230000002792 vascular Effects 0.000 title claims abstract description 7
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 14
- 229920001308 poly(aminoacid) Polymers 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- 229920002994 synthetic fiber Polymers 0.000 claims abstract description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 9
- 239000005017 polysaccharide Substances 0.000 claims abstract description 9
- 230000035699 permeability Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 9
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 6
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 6
- 108010039918 Polylysine Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920000656 polylysine Polymers 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920002714 polyornithine Polymers 0.000 claims description 3
- 108010055896 polyornithine Proteins 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241001315286 Damon Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
Definitions
- Microcapsules consisting of saccharide polymers and polyaminoacids, or other substances such as agarose polymers, suitable to contain hormone producing living cells are known.
- Microcapsules of such a type are produced and commercialized for instance by the firm Damon Biotech of Boston under the Trade Mark
- Encapcell The features of said microcapsules allow the cells to be protected from possible rejection events, and enable the necessary cell metabolic supply and the release of the hormones secreted by the same cells.
- the microcapsules implanted in the body are surrounded by a connective reaction tissue which prevents both the cell metabolic supply and the release of the secreted hormones;
- biocompatible synthetic double-wall vascular prostheses characterized in that they comprise an outer tubular element 1 made of low-porosity synthetic material and an internal tubular element 2 coaxial with the former and consisting of high porosity synthetic material imbued with polysaccharide material coated with, polyaminoacids, the space comprised between said element 1 and said element 2 being filled with hormone-secreting cells 3-
- the process for preparing said prostheses is characterized in that it comprises the following stages: a) inside a tubular element 1 made of low-porosity synthetic material, a tubular web 2 of high-porosity synthetic material is placed; b) within said tubular web, a mandrel is introduced of such a diameter that the web adheres to it; c) the web is coated with a thin layer of saccharide polymer; d) the mandrel is removed; e) a further layer consisting of a polyaminoacid is sedimented upon said saccharide polymer layer ; f) the space comprised between the element 1 and the element 2 is filled with hormone-secreting cells.
- prosthesis exhibits the property of being biocompatible and moreover the element 2 shows a controlled permeability-
- the prosthesis is employed to make arteriovenous fistulae in which the feasibility of the metabolic exchange between blood and cells 3 and the release into the blood stream of the hormones secreted by the same cells is enabled.
- FIG. 1 is a schematic illustration of a prosthesis according to the present invention. Reference is made to the numbers in said figure.
- a tubular web 2 consisting of polyester fibres and including free spaces of size ranging from 10 to 100 ⁇ m within the fibres, is placed into a tubular element 1 consisting of PTFE or of low porosity tissue.
- tubular web 2 Into the tubular web 2 there is located a mandrel of plastic material or glass having such a diameter that the web adheres to it.
- the web is soaked with a polysaccharide gel, preferably sodium alginate, in order to fill up the free spaces within the fibres.
- a polysaccharide gel preferably sodium alginate
- the mandrel is thereafter removed and the thus obtained structure 2 is coated with a thin layer of a polyaminoacid, preferably polylysine or polyornithine.
- a polyaminoacid preferably polylysine or polyornithine.
- mandrel is intended to prevent the polysaccharide material, or any other, from flowing into the lumen of the element
- the prosthesis manufactured according to the disclosed technique and making use of the described substances exhibits structural properties, biocompatibility and porosity such as to allow it to be successfully employed as prosthesis for arteriovenous fistulae.
- the coating of the element 2 with polylysine (MW 15000) imparts a good permeability for dextrane having MW 40 000 while maintaining the element 2 actually proof against dextrane having MW higher than 60 000.
- the permeability may be changed in either direction.
- the permeability of the element 2 may be adjusted up to a MW of 70 000 thus allowing the transfer of metabolic products from the inside to the outside and vice versa, not however the exchange of immunoglobulins or any other high molecular weight substance.
- the thickness of the element 2 needs in any case to be lower than 100 ⁇ m in order to allow the metabolic exchanges in both direction.
- the inner diameter of the element 2 is comprised between 4 and 8 mm while the inner diameter of the element 1 is comprised between 10 and 14 mm.
- the tubular element 2 consists of a small tube of PTFE having a lamellar structure including free spaces of 10 to 100 ⁇ m, which impart to the same a high porosity.
- the impregnation with polysaccharide material is achieved by dipping the small tube into the same material and then by submitting it to the vacuum in order to facilitate the filling of the free spaces of the PTFE with the material itself .
- the polyaminoacid is then sedimented on the thus obtained element.
- Finally the space comprised between the tubular element 1 and the tubular element 2 is filled with hormone-secreting cells 3 t which may be either free or microincapsulated.
- prostheses which are employed to make arteriovenous fistulae , allow the supply of oxygen and any other product necessary to the cellular metabolism from the blood stream to said cells and the release in opposite direction of the hormones secreted by the same cells .
- the inner surface of element 2 may be coated by a monolayer similar to an endothelial one.
- a specifically favourable application of the prostheses of the present invention is obtained when the microcapsules contain Langherans 1 islands cells which secret insulin.
- the disclosed technique can be applied for manufacturing any surface of synthetic material coated with biocompatible substances .
Abstract
Biocompatible synthetic double-wall vascular prostheses comprising an outer tubular element (1) made of low-porosity synthetic material and an internal tubular element (2) coaxial with the former and consisting of high porosity synthetic material imbued with polysaccharide material coated with polyaminoacids which impart to the element (2) the feature of a controlled permeability, the space comprised between said element (1) and said element (2) being filled with hormone-secreting cells (3).
Description
BIOCOMPATIBLE SYNTHETIC DOUBLE-WALL VASCULAR PROSTHESIS CONTAINING
HORMONE-SECRETING CELLS
PRIOR ART
Microcapsules consisting of saccharide polymers and polyaminoacids, or other substances such as agarose polymers, suitable to contain hormone producing living cells are known.
Microcapsules of such a type are produced and commercialized for instance by the firm Damon Biotech of Boston under the Trade Mark
Encapcell. The features of said microcapsules allow the cells to be protected from possible rejection events, and enable the necessary cell metabolic supply and the release of the hormones secreted by the same cells.
However the implant of said microcapsules into the human body brings about problems among which the following are highlighted:
1) the microcapsules implanted in the body are surrounded by a connective reaction tissue which prevents both the cell metabolic supply and the release of the secreted hormones;
2) the microcapsules injected into a body cavity such as the peritoneal space tend to sediment and to concentrate in a deep limited area thus eliciting a strong connective reaction which wraps them.
SUMMARY OF THE INVENTION
It has now been found that the problems of the prior art may be avoided by employing biocompatible synthetic double-wall vascular
prostheses characterized in that they comprise an outer tubular element 1 made of low-porosity synthetic material and an internal tubular element 2 coaxial with the former and consisting of high porosity synthetic material imbued with polysaccharide material coated with, polyaminoacids, the space comprised between said element 1 and said element 2 being filled with hormone-secreting cells 3-
The process for preparing said prostheses is characterized in that it comprises the following stages: a) inside a tubular element 1 made of low-porosity synthetic material, a tubular web 2 of high-porosity synthetic material is placed; b) within said tubular web, a mandrel is introduced of such a diameter that the web adheres to it; c) the web is coated with a thin layer of saccharide polymer; d) the mandrel is removed; e) a further layer consisting of a polyaminoacid is sedimented upon said saccharide polymer layer ; f) the space comprised between the element 1 and the element 2 is filled with hormone-secreting cells.
Thus obtained prosthesis exhibits the property of being biocompatible and moreover the element 2 shows a controlled permeability-
The prosthesis is employed to make arteriovenous fistulae in which the feasibility of the metabolic exchange between blood and cells 3 and the release into the blood stream of the hormones secreted
by the same cells is enabled.
DETAILED DESCRIPTION OF THE INVENTION
The features of, and the advantages implied by the vascular prostheses and by the process for manufacturing the same, according to the present invention, will be more clearly evident in the light of the following detailed description also with reference to the enclosed figure 1.
Figure 1 is a schematic illustration of a prosthesis according to the present invention. Reference is made to the numbers in said figure. A tubular web 2, consisting of polyester fibres and including free spaces of size ranging from 10 to 100 μm within the fibres, is placed into a tubular element 1 consisting of PTFE or of low porosity tissue.
Into the tubular web 2 there is located a mandrel of plastic material or glass having such a diameter that the web adheres to it.
The web is soaked with a polysaccharide gel, preferably sodium alginate, in order to fill up the free spaces within the fibres.
The mandrel is thereafter removed and the thus obtained structure 2 is coated with a thin layer of a polyaminoacid, preferably polylysine or polyornithine.
The use of the mandrel is intended to prevent the polysaccharide material, or any other, from flowing into the lumen of the element
2, assuring in this way the result of a perfectly cylindrical internal surface free of any roughness.
The prosthesis manufactured according to the disclosed technique and making use of the described substances, exhibits structural properties, biocompatibility and porosity such as to allow it to be successfully employed as prosthesis for arteriovenous fistulae. Particularly the coating of the element 2 with polylysine (MW 15000) imparts a good permeability for dextrane having MW 40 000 while maintaining the element 2 actually proof against dextrane having MW higher than 60 000. By making use of other polyaminoacids, the permeability may be changed in either direction. Practically the permeability of the element 2 may be adjusted up to a MW of 70 000 thus allowing the transfer of metabolic products from the inside to the outside and vice versa, not however the exchange of immunoglobulins or any other high molecular weight substance. The thickness of the element 2 needs in any case to be lower than 100 μm in order to allow the metabolic exchanges in both direction. The inner diameter of the element 2 is comprised between 4 and 8 mm while the inner diameter of the element 1 is comprised between 10 and 14 mm. According to an alternative embodiment, the tubular element 2 consists of a small tube of PTFE having a lamellar structure including free spaces of 10 to 100 μm, which impart to the same a high porosity.
The impregnation with polysaccharide material is achieved by dipping the small tube into the same material and then by submitting it to the vacuum in order to facilitate the filling of
the free spaces of the PTFE with the material itself . The polyaminoacid is then sedimented on the thus obtained element. Finally the space comprised between the tubular element 1 and the tubular element 2 is filled with hormone-secreting cells 3 t which may be either free or microincapsulated.
Thus obtained prostheses , which are employed to make arteriovenous fistulae , allow the supply of oxygen and any other product necessary to the cellular metabolism from the blood stream to said cells and the release in opposite direction of the hormones secreted by the same cells .
Moreover because of the haematic flow, the inner surface of element 2 may be coated by a monolayer similar to an endothelial one. A specifically favourable application of the prostheses of the present invention is obtained when the microcapsules contain Langherans 1 islands cells which secret insulin.
Furthermore the disclosed technique can be applied for manufacturing any surface of synthetic material coated with biocompatible substances .
Claims
1. Biocompatible synthetic double-wall vascular prosthesis characterized in that it comprises an outer tubular element (1) made of low-porosity synthetic material and an internal tubular element (2) coaxial with the former and consisting of high porosity synthetic material imbued with polysaccharide material coated with polyaminoacids, the space comprised between said element (1) and said element (2) being filled with hormone-secreting cells (3).
2. Prosthesis according to claim 1, characterized in that said tubular element (1) consists of PTFE.
3- Prosthesis according to claim 1, characterized in that said tubular element (2) consists of a tubular web of polyester fibres including free spaces of size comprised between 10 and 100 μm within the fibres.
4. Prosthesis according to claim 1, characterized in that said tubular element (2) consists of a small tube of PTFE with lamellar structure including free spaces of 10 to 100 μm.
5> Prosthesis according to claim 1, characterized in that said polysaccharide material is sodium alginate.
6. Prosthesis according to claim 1, characterized in that said polyaminoacid is polylysine or polyornithine.
7. Prosthesis according to claim 1, characterized in that said tubular element (2) has a thickness lower than 100 μm.
8. Prosthesis according to claim 1, characterized in that said tubular element (2) has a inner diameter comprised between 4 and 8
mm and that said tubular element (1) has an inner diameter comprised between 10 and 14 mm.
9. Prosthesis according to claim 1, characterized in that the treatment with the polysaccharide material and polyaminoacid adjusts the permeability of the tubular element (2) up to a MW of 70000.
10. Prosthesis according to claim 1, characterized in that said cells (3) are microincapsulated.
11. Process for preparing biocompatible synthetic double-wall vascular prostheses containing hormone-secreting cells characterized in that: a) inside a tubular element (1) made of low-porosity synthetic material, a tubular web (2) of high-porosity synthetic material is placed; b) within said tubular web, a mandrel is introduced of such a diameter that the web adheres to it; c) the web is coated with a thin layer of saccharide polymer; d) the mandrel is removed; e) a further layer consisting of a polyaminoacid is sedimented upon said saccharide polymer layer ; f) the space comprised between the element (1) and the element (2) is filled with hormone-secreting cells.
12. Process according to claim 11, characterized in that said tubular element (1) consists of PTFE.
13. Process according to claim 11, characterized in that said
tubular web (2) consists of polyester fibres and includes free spaces within the fibres of size comprised between 10 and 100 μm.
14. Process according to claim 11, characterized in that said polysaccharide material is sodium alginate.
1 . Process according to claim 11, characterized in that said polyaminoacid is polylysine or polyornithine.
16. Process according to claim 11, characterized in that said tubular web (2) has a inner diameter comprised between 4 and 8 mm and that said tubular element (1) has an inner diameter comprised between 10 and 14 mm.
17. Process according to claim 11, characterized in that said tubular web (2) is replaced by a small tube of PFTE with lamellar structure including free spaces of 10 to 100 μm.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22228A/90 | 1990-11-29 | ||
| IT02222890A IT1244808B (en) | 1990-11-29 | 1990-11-29 | BIOCOMPATIBLE SYNTHETIC VASCULAR PROSTHESIS WITH DOUBLE WALL CONTAINING HORMONOUS SECURING CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1992009311A1 true WO1992009311A1 (en) | 1992-06-11 |
Family
ID=11193359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1991/002258 WO1992009311A1 (en) | 1990-11-29 | 1991-11-27 | Biocompatible synthetic double-wall vascular prosthesis containing hormone-secreting cells |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | IT1244808B (en) |
| WO (1) | WO1992009311A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0633032A1 (en) * | 1993-06-25 | 1995-01-11 | Sumitomo Electric Industries, Ltd. | Antibacterial vascular prosthesis and surgical suture |
| US5527324A (en) * | 1994-09-07 | 1996-06-18 | Krantz; Kermit E. | Surgical stent |
| US5679122A (en) * | 1993-08-14 | 1997-10-21 | Minnesota Mining & Manufacturing Company | Filter for the filtration of a fluid flow |
| WO1998010804A1 (en) * | 1996-09-13 | 1998-03-19 | Meadox Medicals, Inc. | Improved bioresorbable sealants for porous vascular grafts |
| US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
| US6316522B1 (en) | 1997-08-18 | 2001-11-13 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
| AT411328B (en) * | 2000-07-12 | 2003-12-29 | Universitaetsklinikum Freiburg | TUBE SYSTEM FOR THE RECONSTRUCTION OF A URINE TUBE |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982003764A1 (en) * | 1981-05-08 | 1982-11-11 | Massachusetts Inst Technology | Fabrication of living blood vessels and glandular tissues |
| EP0147939A2 (en) * | 1983-11-15 | 1985-07-10 | JOHNSON & JOHNSON | Implantable module for gylcemia regulation |
| CA1215922A (en) * | 1984-05-25 | 1986-12-30 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
| EP0406665A1 (en) * | 1989-07-04 | 1991-01-09 | Giovanni Brotzu | Vascular prosthesis containing in the wall microcapsules, including hormoneproducing cells |
| WO1991000119A1 (en) * | 1989-06-30 | 1991-01-10 | Baxter International Inc. | Implantable device |
-
1990
- 1990-11-29 IT IT02222890A patent/IT1244808B/en active IP Right Grant
-
1991
- 1991-11-27 WO PCT/EP1991/002258 patent/WO1992009311A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982003764A1 (en) * | 1981-05-08 | 1982-11-11 | Massachusetts Inst Technology | Fabrication of living blood vessels and glandular tissues |
| EP0147939A2 (en) * | 1983-11-15 | 1985-07-10 | JOHNSON & JOHNSON | Implantable module for gylcemia regulation |
| CA1215922A (en) * | 1984-05-25 | 1986-12-30 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
| WO1991000119A1 (en) * | 1989-06-30 | 1991-01-10 | Baxter International Inc. | Implantable device |
| EP0406665A1 (en) * | 1989-07-04 | 1991-01-09 | Giovanni Brotzu | Vascular prosthesis containing in the wall microcapsules, including hormoneproducing cells |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0633032A1 (en) * | 1993-06-25 | 1995-01-11 | Sumitomo Electric Industries, Ltd. | Antibacterial vascular prosthesis and surgical suture |
| US5584877A (en) * | 1993-06-25 | 1996-12-17 | Sumitomo Electric Industries, Ltd. | Antibacterial vascular prosthesis and surgical suture |
| US5679122A (en) * | 1993-08-14 | 1997-10-21 | Minnesota Mining & Manufacturing Company | Filter for the filtration of a fluid flow |
| US5527324A (en) * | 1994-09-07 | 1996-06-18 | Krantz; Kermit E. | Surgical stent |
| WO1998010804A1 (en) * | 1996-09-13 | 1998-03-19 | Meadox Medicals, Inc. | Improved bioresorbable sealants for porous vascular grafts |
| US5851229A (en) * | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
| US6028164A (en) * | 1997-08-18 | 2000-02-22 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
| US6005020A (en) * | 1997-08-18 | 1999-12-21 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
| US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
| US6316522B1 (en) | 1997-08-18 | 2001-11-13 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
| US6403758B1 (en) | 1997-08-18 | 2002-06-11 | Scimed Life Systems, Inc. | Bioresorbable compositions for implantable prostheses |
| US6660827B2 (en) | 1997-08-18 | 2003-12-09 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
| US6946499B2 (en) | 1997-08-18 | 2005-09-20 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
| US7109255B2 (en) | 1997-08-18 | 2006-09-19 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
| AT411328B (en) * | 2000-07-12 | 2003-12-29 | Universitaetsklinikum Freiburg | TUBE SYSTEM FOR THE RECONSTRUCTION OF A URINE TUBE |
| US6939381B2 (en) | 2000-07-12 | 2005-09-06 | Universitatsklinikum Frieburg | Tube system for reconstructing of hollow organs |
Also Published As
| Publication number | Publication date |
|---|---|
| IT9022228A1 (en) | 1992-05-30 |
| IT9022228A0 (en) | 1990-11-29 |
| IT1244808B (en) | 1994-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5061276A (en) | Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation | |
| US9567447B2 (en) | Outer layer having entanglement of hydrophobic polymer host and hydrophilic polymer guest | |
| EP1511523B1 (en) | Implantable device with porous membrane rendered hydrophilic | |
| US4878907A (en) | Synthetic vascular prosthesis | |
| EP0118458B1 (en) | Biocompatible, antithrombogenic materials suitable for reconstructive surgery | |
| EP0241838B1 (en) | Antithrombogenic material | |
| US4816339A (en) | Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation | |
| JP4383851B2 (en) | Polysaccharide biomaterial and use thereof | |
| EP0230635B1 (en) | Tubular prosthesis having a composite structure | |
| US5851229A (en) | Bioresorbable sealants for porous vascular grafts | |
| US6797311B2 (en) | Process for impregnating a porous material with a cross-linkable composition | |
| US5104403A (en) | Vascular prosthesis containing in the wall microcapsules, including hormone-producing cells | |
| WO1986002843A1 (en) | A method of producing a mono- or multilayered prosthesis material and the material hereby obtained | |
| EP1670385A2 (en) | Novel porous biomaterials | |
| JP2004523291A (en) | Manufacturing method of medical implant | |
| WO1992009311A1 (en) | Biocompatible synthetic double-wall vascular prosthesis containing hormone-secreting cells | |
| US4904272A (en) | Crosslinked polyurethane medical prosthesis | |
| US5201778A (en) | Vascular prosthesis containing in the wall microcapsules, including hormone-producing cells | |
| CA1299937C (en) | Antithrombogenic material | |
| Wu et al. | Colloid and Interface Science Communications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |